Showing 3581-3590 of 7329 results for "".
- Tralokinumab Data for H&N AD Presented at EADVhttps://practicaldermatology.com/news/tralokinumab-data-hn-ad-presented-eadv/2468323/Nine-month interim data from the TRACE study, showing that tralokinumab/tralokinumab-ldrm reduced the severity of moderate-to-severe atopic dermatitis (AD) in the head and neck region of the body (H&N), were shared through one of LEO Pharma’s five late-breaking oral presentations at the 33rd
- Joseph H. Boccuzi Appointed to Allergan plc Board of Directorshttps://practicaldermatology.com/news/joseph-h-boccuzi-appointed-to-allergan-plc-board-of-directors/2458116/Allergan plc has named Joseph H. Boccuzi to its Board of Directors, effective immediately. Mr. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with
- FDA Clears Fotona's StarWalker MaQX Ultra Performance Q-Switched Systemhttps://practicaldermatology.com/news/fda-clears-fontinas-starwalker-maqx-ultra-performance-q-switched-system/2458038/The FDA has cleared Fotona's StarWalker MaQX Q-Switched laser system for treating tattoos, pigmented and vascular lesions, acne and scar revision, and permanent hair reduction. The Verde 532 mode in a "tattoo laser" is exclusive to the MaQX. Sales in the US will begin immediately. T
- CMS Assigns Q-code to Fish Skin Technology, Kerecis Reportshttps://practicaldermatology.com/news/20141113-cms_assigns_q-code_to_fish_skin_technology_kerecis_reports/2459065/The new Omega3 tissue-regeneration material from Kerecis Limited—dubbed fish skin—has received a "Q" code from the Centers for Medicare and Medicaid Services (CMS). Kerecis Omega3 Wound, indicated for the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds, has b
- It’s Gold and Silver for Sebacia with Sienna Acquisitionhttps://practicaldermatology.com/news/its-gold-and-silver-for-sebacia-with-sienna-acquisition/2460247/Mr. Chuck Abraham is the new Chief Executive Officer of Sebacia, Inc. Sebacia is preparing a targeted commercial launch of Sebacia Microparticles in the US for treatment of acne early in 2020 with plans to expand to additional territories later in th
- What New Secukinumab Data Mean for HS Patients: A Q&A with Dr. April Armstronghttps://practicaldermatology.com/news/what-new-secukinumab-data-mean-for-hs-patients-a-qa-with-dr-april-armstrong/2486412/In the following Q&A, Dr. April Armstrong, professor and chief of dermatology at UCLA and a study coauthor, talks with Practical Dermatology about the importance of new secukinumab data for patients with hidradenitis suppurativa (HS). Speaking on UCB's recently announced top
- Alma Lasers Hosts Special Programs at the 34th ASLMS Conference in Phoenixhttps://practicaldermatology.com/news/20140403-alma_lasers_hosts_special_programs_at_the_34th_aslms_conference_in_phoenix/2459279/The ASLMS, provider of laser, light-based, radio frequency and ultrasound technologies, invites guests to hear from leading experts. Michael Gold, of Gold Skin Care in Nashville, Tennessee, will moderate the night's discussion. Others include: Macrene Alexiades-Armenakas, MD, director a
- LEO Pharma U.S. Welcomes Judit H. Nyirady as Vice President of Medical Strategy & Scientific Affairshttps://practicaldermatology.com/news/leo-pharma-us-welcomes-judit-h-nyirady-as-vice-president-of-medical-strategy-scientific-affairs/2458194/Judit H. Nyirady, MD, MBA, is the new Vice President of Medical Strategy & Scientific Affairs at LEO Pharma Inc. In this role, she will be responsible for the medical and scientific affairs strategies for LEO Pharma in the United States, as well
- New Combo Therapy Beats Out Gold Standard Treatment For AKshttps://practicaldermatology.com/news/new-combo-therapy-beats-out-gold-standard-treatment-for-aks/2458360/Combining a cream formulation of 5-fluorouracil with a synthetic form of vitamin D called calcipotriol may trigger a robust immune response against actinic keratosis, according to research out of rom Washington University School of Medicine in St. Louis and Harvard Medical School in Boston.
- Stratpharma Inc. USA Names Michael Flowers President of North American Commercial Operationshttps://practicaldermatology.com/news/stratpharma-inc-usa-names-michael-flowers-president-of-north-american-commercial-operations/2461185/Michael Flowers is now President of North America Commercial Operations for Stratpharma Inc. in the United States. Mr. Flowers joins Stratpharma from WSI, where he served as Chief Commercial Officer. Stratpharma Inc. USA is the US subsidi